一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Trastuzumab Deruxtecan；pembrolizumab；Pemetrexed；Platinum Chemotherapy，当前状态为招募中。登记地点显示中国北京、长春、长沙、成都等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Trastuzumab Deruxtecan；pembrolizumab；Pemetrexed；Platinum Chemotherapy · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- China-Japan Friendship hospital · 北京
- Jilin Cancer Hospital · 长春
- The First Hospital of Jilin University · 长春
- Hunan Cancer Hospital · 长沙
- Sichuan Cancer Hospital · 成都
- West China Hospital, Sichuan University · 成都
- Chongqing University Cancer Hospital · 重庆
- Nanfang Hospital of Southern Medical University · 广州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Anhui Provincial Hospital · 合肥
- The Second Hospital of Anhui Medical University · 合肥
- Hong Kong Integrated Oncology Centre · 香港
- Cancer Hospital of Shandong First Medical University · 济南
- Hong Kong United Oncology Centre · 佐敦
- Linyi Cancer Hospital · 临沂
- The First Affiliated Hospital of Nanchang University · 南昌
- The Second Affiliated Hospital of Nanchang University · 南昌
- Jiangsu Province Hospital · 南京
- The Second People's Hospital of Neijiang · 内江
- Shanghai East Hospital · 上海
- The First Hospital of China Medical University · 沈阳
- Liaoning Cancer Hospital & Institute · 沈阳
- Shanxi Provincial Cancer Hospital · 太原
- Tianjin Medical University General Hospital · 天津
- Hubei Cancer Hospital · 武汉
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology · 武汉
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Xiangyang Central Hospital · 襄阳
- Henan Cancer Hospital · 郑州
公开的入选条件
- 1. Sign and date the Tissue Screening ICF, prior to any Tissue Screening procedure. Sign and date the Main ICF, prior to the start of any trial-specific qualification procedures.
- Sign and date the Optional PGx ICF (included in the Main ICF) prior to any PGx procedure, and the Pregnant Partner ICF, if applicable.
- 2. Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old.
- 3. Histologically documented non-squamous locally advanced unresectable or metastatic
- NSCLC and meets all of the following criteria:
- Has Stage IV NSCLC disease or Stage IIIB or IIIC disease but is not a candidate for surgical resection or definitive chemoradiation at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition). Has no known AGAs (based on the
- Has no known HER2 mutation based on existing test results (if approved or validated local test is available). Note: Participants with mixed histology are eligible if non-squamous NSCLC is the predominant histology. Mixed tumors will be classified based on the
- 4. Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Participants who received adjuvant or neoadjuvant therapy other than those listed below, including ICI (ie, anti-PD-1/PD-L1) or a platinum-based regimen, ar
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06899126；登记信息更新于 2026-09-15。